| Literature DB >> 35886382 |
Suzumi Okuda1, Miwako Tunematsu1, Keiji Tabuchi2, Toshio Kobayashi3, Masayuki Kakehashi1, Hisae Nakatani1.
Abstract
This study examined the effectiveness of a new health promotion program, which is a collective intervention program aimed at improving lifestyle habits. It was designed as a one-year prospective cohort study. This program targeted non-obese persons at risk of developing lifestyle-related diseases and participants with hypertension, dyslipidemia, or hyperglycemia who were not included in the specific health guidance system in Japan. The Wadaiko rhythm exercise, which is a traditional performing art, is incorporated into this intervention as an enjoyable routine that can help participants continue the program, preventing them from dropping out. After a one-year follow-up, the effectiveness of the health promotion program was evaluated in 18 participants (2 males, 16 females; mean age 65.2 ± 3.4 years) and 92 controls. The results showed that triglyceride in the intervention group significantly decreased (-24.5 mg/dL; p = 0.02; 95% confidence interval [CI], -44.73 to -4.27) and high-density lipoprotein cholesterol significantly increased (+6.1 mg/dL; p < 0.01; 95% CI, 2.46 to 9.65), although levels in the control group did not change. These results suggest that the health promotion program could contribute to lifestyle habit improvements in those who are excluded from receiving specific health guidance.Entities:
Keywords: Wadaiko rhythm exercise; health behavior; health promotion; lifestyle habits; specific health guidance inapplicable individuals
Mesh:
Year: 2022 PMID: 35886382 PMCID: PMC9321626 DOI: 10.3390/ijerph19148520
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Study workflow diagram showing inclusion and exclusion criteria.
Baseline characteristics.
| Characteristic | Intervention Group | Control Group | |
|---|---|---|---|
| Age, years (SD) | 65.2 (3.4) | 64.1 (4.5) | 0.39 |
| Sex, female, | 16 (88.9) | 59 (64.1) | 0.05 |
| Body mass index, kg/cm2 (SD) | 23.6 (3.6) | 22.1 (2.6) | 0.21 |
| TG, mg/dL (SD) | 112.6 (39.4) | 105.2 (48.6) | 0.21 |
| HDL-C, mg/dL (SD) | 64.8 (14.3) | 66.1 (15.5) | 0.75 |
| LDL-C, mg/dL (SD) | 140.8 (30.5) | 131.9 (29.5) | 0.24 |
| HbA1c, % (SD) | 5.87 (0.40) | 5.61 (0.46) | <0.01 |
| Anti-hypertensive drugs, | 8 (44.4) | 24 (26.1) | 0.16 |
| Insulin injections or antihyperglycemic drugs, | 4 (22.2) | 5 (5.4) | 0.04 |
| Cholesterol-reducing drugs, | 8 (44.4) | 28 (30.4) | 0.28 |
| History of stroke, | 0 (0.0) | 3 (3.3) | 1 |
| History of heart disease, | 2 (11.1) | 3 (3.3) | 0.19 |
| History of chronic kidney failure, | 0 (0.0) | 0 (0.0) | — |
| History of smoking, | 3 (16.7) | 31 (33.7) | 0.18 |
| Exercise habits, | 9 (50.0) | 34 (37.0) | 0.31 |
Abbreviation: TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c. a Taking prescription drugs. b Those who responded “yes” had been exercising for over a year, at least twice a week, with each session lasting more than 30 min. For continuous variables, the t-test was performed for those with normality, while the Mann–Whitney U test was performed for those without normality. Fisher’s exact test was performed for the ratio.
Blood measurements at baseline and after 1 year.
| Baseline | 1 Year | 95% CI | ||||
|---|---|---|---|---|---|---|
| LL | UL | |||||
| Intervention group | TG, mg/dL (SD) | 112.61 (39.38) | 88.11 (28.47) | 0.02 * | −44.73 | −4.27 |
| 111.5 (91.25–121.25) | 86.0 (68.75–112.5) | 0.02 * | ||||
| HDL-C, mg/dL (SD) | 64.83 (14.31) | 70.89 (14.66) | <0.01 ** | 2.46 | 9.65 | |
| 60.5 (56.25–75.50) | 70 (64.00–78.25) | <0.01 ** | ||||
| LDL-C, mg/dL (SD) | 140.83 (30.46) | 129.06 (29.71) | 0.13 | −27.38 | 3.82 | |
| 140.5 (127–157.5) | 130.5 (111.50–141.75) | 0.21 | ||||
| HbA1c, % (SD) | 5.87 (0.40) | 5.82 (0.46) | 0.41 | −0.19 | 0.08 | |
| 5.8 (5.650–5.975) | 5.75 (5.5–5.800) | 0.07 | ||||
| Control group | TG, mg/dL (SD) | 105.17 (48.60) | 106.25 (50.76) | 0.80 | −7.22 | 9.38 |
| 93.0 (72.00–129.75) | 95.5 (70.50–129.0) | 0.97 | ||||
| HDL-C, mg/dL (SD) | 66.12 (15.47) | 64.41 (15.85) | 0.02 * | −3.19 | −0.22 | |
| 66.0 (55.75–74.25) | 61 (53.75–74.00) | 0.045 | ||||
| LDL-C, mg/dL (SD) | 131.86 (29.54) | 128.02 (27.79) | 0.07 | −7.98 | 0.31 | |
| 133.0 (110–152.0) | 128.5 (109.75–145.00) | 0.10 | ||||
| HbA1c, % (SD) | 5.61 (0.46) | 5.57 (0.51) | 0.06 | −0.07 | 0.00 | |
| 5.6 (5.375–5.800) | 5.60 (5.3–5.725) | 0.04 * | ||||
Abbreviation: TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; CI, confidence interval; LL, lower limit; UL, upper limit; 95% CI, confidence interval of the difference between baseline and 1 year later. * p < 0.05, ** p < 0.01: Significant difference vs. baseline data. The upper row shows the mean and standard deviation, and the lower row shows the median and interquartile range.
Two-group comparison of changes in blood measurement.
| Intervention Group | Control Group | 95% CI | |||
|---|---|---|---|---|---|
| LL | UL | ||||
| TG, mg/dL (SD) | −24.50 (40.68) | 1.08 (40.08) | 0.02 * | −46.10 | −5.05 |
| −28.5 (−41–9.5) | 0.0 (−24–20.5) | 0.03 * | |||
| HDL-C, mg/dL (SD) | 6.06 (7.23) | −1.71 (7.16) | <0.01 ** | 4.10 | 11.42 |
| 5.5 (1.75–10.75) | −1.0 (−6.00–3.00) | <0.01 ** | |||
| LDL-C, mg/dL (SD) | −11.78 (31.37) | −3.84 (20.00) | 0.17 | −19.27 | 3.39 |
| −5.5 (−15.50–7.75) | −2.0 (−13.25–5.50) | 0.63 | |||
| HbA1c, %; (SD) | −0.06 (0.28) | −0.04 (0.18) | 0.70 | −0.120 | 0.081 |
| −0.1 (−0.2–0.0) | 0.0 (−0.1–0.1) | 0.18 | |||
Abbreviation: TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; CI, confidence interval; LL, lower limit; UL, upper limit; 95% CI, confidence interval of the difference between groups. * p < 0.05, ** p < 0.01: Significant difference two-group comparison. The upper row shows the mean and standard deviation, and the lower row shows the median and interquartile range.
Influential factors of change.
| Variable | TG | HDL-C | LDL-C | HbA1c | ||||
|---|---|---|---|---|---|---|---|---|
| Estimate | Estimate | Estimate | Estimate | |||||
| (Intercept) | 131.810 | 0.044 * | 5.583 | 0.649 | 27.598 | 0.462 | 0.074 | 0.819 |
| Sex | 2.518 | 0.860 | −2.786 | 0.302 | 4.878 | 0.553 | −0.068 | 0.338 |
| Age | −1.517 | 0.093 | 0.020 | 0.905 | −0.603 | 0.245 | −0.001 | 0.902 |
| Body mass index | −2.172 | 0.166 | −0.264 | 0.373 | −0.142 | 0.875 | 0.000 | 0.985 |
| Exercise habits | 8.646 | 0.268 | −0.473 | 0.748 | 5.637 | 0.211 | −0.007 | 0.865 |
| Health promotion program | −22.652 | 0.040 * | 8.038 | <0.001 *** | −7.784 | 0.217 | −0.027 | 0.618 |
| Former smokers | 23.596 | 0.103 | −3.005 | 0.270 | 8.844 | 0.288 | −0.032 | 0.661 |
| Smokers | 20.572 | 0.303 | −4.414 | 0.243 | 13.884 | 0.229 | −0.049 | 0.625 |
| Cholesterol-reducing drugs | 8.511 | 0.339 | 0.319 | 0.849 | 4.750 | 0.355 | −0.020 | 0.647 |
| Anti-hypertensive drugs | −7.491 | 0.431 | 0.899 | 0.616 | 1.205 | 0.826 | −0.069 | 0.147 |
| Insulin injection or antihyperglycemic drugs | 25.318 | 0.090 | 0.045 | 0.987 | −0.892 | 0.917 | 0.208 | 0.006 ** |
| Multiple R-squared | 0.18 | 0.164 | 0.070 | 0.097 | ||||
| Adjusted R-squared | 0.097 | 0.080 | −0.024 | 0.006 | ||||
| F-statistic | 2.168 on 10 and 99 DF | 1.944 on 10 and 99 DF | 0.7418 on 10 and 99 DF | 1.069 on 10 and 99 DF | ||||
| 0.026 | 0.048 | 0.684 | 0.394 | |||||
|
| ||||||||
| (Intercept) | 1.076 | 0.798 | −1.707 | 0.024 * | −0.052 | 0.007 ** | ||
| Health promotion program | −25.576 | 0.015 * | 7.762 | <0.001 *** | Excluded all | |||
| Insulin injection or antihyperglycemic drugs | 0.164 | 0.016 * | ||||||
| Multiple R-squared | 0.053 | 0.140 | 0.053 | |||||
| Adjusted R-squared | 0.045 | 0.133 | 0.044 | |||||
| F-statistic | 6.101 on 1 and 108 DF | 17.64 on 1 and 108 DF | 6 on 1 and 108 DF | |||||
| 0.015 | < 0.001 | 0.016 | ||||||
Abbreviation: TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c. * p < 0.05, ** p < 0.01, *** p < 0.001: Significant difference.